Introduction
Chronic heart failure (CHF) is a clinical syndrome with features of cardiac dysfunction as well as extracardiac manifestations that are consequent on damage to the heart. Advances in our understanding of the pathophysiology of CHF have moved us away from seeing it in purely haemodynamic terms to an appreciation of its multisystemic nature. Patients with CHF have evidence of neurohormonal and in ammatory cytokine activation, which may play a crucial role in the pathogenesis of this syndrome (1, 2) . Many patients with advanced CHF develop a wasting syndrome termed cardiac cachexia which is associated with a particularly poor prognosis (3) and marked endocrine and immune abnormalities (4) . This review article will present the current evidence on the importance of neurohormonal and immune pathways in patients with CHF that lead to an imbalance of catabolic and anabolic metabolism and hence to cachexia. Therapeutic implications will be highlighted.
Immune activation in chronic heart failure
Many studies have shown that CHF is associated with increased circulating levels of proin ammatory cytokines. Cytokines are low molecular weight proteins that can be released by most cell types. Unlike hormones, cytokines are not stored but are secreted in response to speci c stimuli. Cytokines have autocrine and paracrine actions. The cytokines considered the most relevant for the pathogenesis of CHF are tumour necrosis factor-a (TNF) and interleukin-6 (IL-6), which have therefore been the most extensively studied in this disease.
Tumour necrosis factor -a TNF is a 51 kDa trimeric molecule with a half-life of around 30 min. TNF can be quanti ed in the serum or plasma using commercially available assays. Elevated levels of TNF have been documented not only in the circulation (5) but also in the myocardium of patients with CHF (6) . TNF is capable of promoting left ventricular remodelling (7) and it is known to be negatively inotropic (8) . TNF levels are particularly elevated in cachectic CHF patients (5, 9 -10) and have been found to be the strongest predictors of the degree of previous weight loss (9) . Apoptosis is frequently found in the skeletal muscle of CHF patients and is related to an impairment of exercise capacity (11) . Animal experiments have shown that TNF is capable of inducing skeletal muscle wasting and apoptosis (12, 13) . These properties of TNF, therefore, make it an important factor in the pathogenesis of catabolism in CHF, and hence in the development of weight loss (i.e. cachexia).
The actions of TNF are mediated by binding to speci c receptors (TNF receptors 1 and 2) that are present on most cell types (14) . The extracellular domain fragments of both receptors shed from cell surfaces can be detected as soluble forms (sTNFR-1 and -2). At physiological concentrations, sTNFRs appear to stabilize the TNF molecule, thereby prolonging its actions (15) . However, at higher concentrations sTNFRs can inhibit the activity of TNF. In addition, sTNFRs are indicators of long-term immune status. sTNFR-1 is already elevated in stable, non-cachectic CHF patients (16) and has been shown to vary over time to a lesser degree than TNF and IL-6 (17).
Concerning energy metabolism, TNF is known to in uence directly thermogenesis, and to contribute to elevated insulin and leptin levels, the latter being a common feature in patients with CHF (18) . It has been suggested that leptin levels are not elevated in patients with cardiac cachexia when corrected for the amount of fat tissue (19) .
Peripheral vasoconstriction is another important pathophysiologica l phenomenon: as CHF worsens it may contribute to the deterioration in left ventricular function by increasing afterload. TNF may have a pathophysiologica l role as serum levels are inversely related to peripheral blood ow in patients with CHF both during stable disease (21; Fig. 1 ) and at times of decompensation (22) . Peak leg blood ow is also the best predictor of exercise capacity in cachectic patients with heart failure ( Fig. 2) (20) . Several mechanisms contribute to peripheral vasoconstriction and many treatment strategies in CHF are targeted towards these pathways. The links between TNF and a number of the pathological processes underlying the development of CHF suggest that the development of anti-TNF therapies may be of bene t. These therapeutic approaches are discussed later in this review.
Interleukins -1 and -6
The presence of IL-1b mRNA in the coronary arteries and myocardium of patients with dilated cardiomyopathy has been demonstrated, whereas patients with ischaemic heart disease express much less IL-1b (23) . IL-1 has important negative inotropic effects as it has been shown to depress myocardial contractility by stimulating nitric oxide synthase (23) . In addition, IL-1 and TNF both inhibit cardiac myocyte b-adrenergic responsiveness (24) . Interleukin 6 (IL-6) is another proin ammatory cytokine which has been implicated in the pathogenesis of CHF. Patients with CHF have raised circulating IL-6 levels (25, 26) which are associated with a worse New York Heart Association (NYHA) functional class, increased length of hospital stay and poorer left ventricular function (27 -30) . Furthermore, IL-6 may be important in the development of osteoporosis, which is known to occur in CHF patients (31) .
Immune parameters and pr ognosis in chronic heart failure
The search for accurate and independent prognostic markers in CHF is important with regard to monitoring treatment and selecting appropriate patients for transplantation. Studies have shown that elevated levels of plasma TNF, sTNFR-1 and -2, IL-6 and soluble CD14 (the receptor for endotoxin) are markers of impaired survival in patients with CHF (32, 33) . In particular, sTNFR-1 appears to be the strongest and most accurate predictor of survival in CHF independent of established parameters (32) (Fig. 3) . In research settings and serum uric acid (35) or the erythrocyte sedimentation rate (36) .
C ause(s) of in ammatory immune activation in chronic heart failure
The main stimulus for the immune activation in CHF is not known, and at present there are three main theories as to why this occurs. One hypothesis is that the heart is the main source of proin ammatory cytokines. In support of this, it has been shown that the failing myocardium is capable of producing TNF (6) , and in vivo studies have reported that haemodynamic pressure overloading is capable of stimulating TNF mRNA synthesis (37) .
The second hypothesis is that the bowel wall oedema and ischaemia, which occur in CHF as a result of venous congestion, are responsible for bacterial translocation, leading to endotoxin release and subsequent immune activation (38) . In support of this it has been reported that monocytes from patients with heart failure are more sensitive than normal to stimuli such as lipopolysaccharide s (LPS) (39 -41) . The evidence for this hypothesis is further supported by the nding that there are elevated concentrations of endotoxin (LPS) and in ammatory cytokines in patients during an acute oedematous exacerbation (42) . Endotoxin levels are normalized by intensive diuretic therapy in these patients (42) . Endotoxin is also known to be able to induce synthesis of TNF mRNA in the myocardium in vivo (43) . If this hypothesis holds true, it opens up a variety of possibilities for novel therapeutic strategies directed against the bacteria in the bowel wall, endotoxin itself or the binding of endotoxin to cells of the immune system (14, 42) . Because lipoproteins can form micelles around endotoxin and block its bioactivity, according to the endotoxin-lipoprotein hypothesis, lipoproteins of all types [including low-density lipoprotein (LDL)] may have direct bene cial effects in CHF patients (44) . In correlation studies, this idea has been supported (45) .
The third proposed hypothesis postulates that extramyocardial cytokine production due to tissue hypoxia may be the primary stimulus for increased TNF production in CHF patients (46, 47) . This is supported by the nding that tissue hypoxia and free radical production are potent stimuli for the generation of cytokine release via nuclear factorkB (NF-kB) dependent pathways (14) . It may, of course, be the case that more than one mechanism is involved in causing the immune activation that occurs in heart failure.
with regard to focused clinical trials, the measurement of soluble TNF receptors may be an ideal measure to de ne patients who are likely to bene t from anti-TNF treatment. However, such assessments are not available in routine clinical practice as they remain relatively expensive and time consuming. Therefore, most would aim to use biochemical surrogate markers of in ammation instead. The latter could be C-reactive protein (34),
Neurohormonal activation
Several neurohormonal changes, including raised catecholamine levels, overactivity of the renin -angiotensin -aldosterone system and elevation of natriuretic peptides, occur when heart failure becomes chronic (48) . According to the neurohormonal hypothesis (49) , heart failure progresses owing to the deleterious effects of the activated endogenous neurohormonal system on the heart and circulation. Several studies have found neurohormonal activation to be strongly related to mortality (50, 51) . Nevertheless, a drug's ability to reduce plasma catecholamine levels is not directly related to a mortality bene t of such a drug (52) . Both adrenaline (epinephrine) and noradrenaline (norepinephrine) can cause increases in metabolic rate (53) , with levels being markedly raised in CHF patients with cardiac cachexia (9) . In addition, plasma levels of cortisol and aldosterone as well as plasma renin activity are particularly elevated in CHF patients with cardiac cachexia (9) . These data suggest a speci c association between the development of body wasting and the presence of neurohormonal activation in CHF patients.
In ammatory cytokines are well known to have signi cant interactions with neurohormonal pathways in CHF. Insulin resistance is a recognized nding in patients with CHF (54) and has been suggested to be of prognostic value (55) . TNF levels correlate positively with the degree of insulin resistance in CHF and may be an important aetiological factor, as has been shown in the context of obesity-related insulin resistance (56) . Moreover, there are particular abnormalities of the growth hormone (GH):insulin-like growth factor-I (IGF-I) axis in cachectic CHF patients. GH levels are raised, whereas IGF-I levels are not altered or may even be reduced, implying a picture of acquired GH resistance (9, 57) . In addition, the abnormalities of the GH:IGF-I system are closely linked to abnormal plasma levels of in ammatory cytokine in CHF patients (58) . Recent studies have been unsuccessful in achieving symptomatic bene ts through the administration of GH (in low doses) in CHF patients (59, 60) . Anabolic high-dose GH therapy is theoretically considered to be indicated in cachectic CHF patients, but this therapy is not without risk (57) . Disorders of steroid metabolism are present in patients with CHF and directly relate to the degree of in ammatory cytokine activation in this condition (61) . Catabolic stress hormones, such as noradrenaline, adrenaline and cortisol are consistently elevated in patients with cardiac cachexia compared with non-cachectic CHF patients, whereas levels of the anabolic hormone dehydroepiandrosterone (DHEA) are reduced (9) . The cortisol: DHEA ratio correlates positively with TNF levels, while both of these indices correlate negatively with the body mass index (61) . Steroid hormone alterations as re ected in the cortisol:DHEA ratio are potentially important in regulating patterns of immune activation, in uencing the balance of Th1 and Th2 cells (62) . It has been proposed that this alteration in the metabolic balance between catabolism and anabolism in CHF, and by association TNF, is a key factor in the development of cardiac cachexia (4).
Modulation of neurohormonal and immune pathways in chronic heart failure patients
Previously, the bene cial effects of drugs used in the treatment of CHF were explained solely by their haemodynamic effects. However, as it is becoming clear that neurohormonal and immune pathways may play an important role in the pathophysiology of CHF, the effects of drugs on these systems are being investigated.
Angiotensin II is a potent stimulator of both the immune and neurohormonal axes, and therefore it may be anticipated that treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor antagonists would have important effects on these pathways. Treatment with ACE inhibitors is known to reduce circulating levels of atrial and brain natriuretic peptides (63, 64) , TNF (65) and IL-6 (66), and it has been shown that ACE inhibitors can restore depressed levels of circulating IGF-I in patients with CHF (67) . Recently, Tsutamoto et al. investigated the effects of candesartan, an angiotensin II type 1 receptor antagonist, on cytokine parameters in 23 patients with mild to moderate CHF. In this study it was demonstrated that candesartan therapy resulted in reduced plasma levels of TNF, IL-6 and brain natriuretic peptides (68) . However, caution must be exercised when trying to interpret the signi cance of changes in the levels of immune and neurohormonal parameters. For instance, spironolactone (a competitive aldosterone receptor antagonist) is known to be bene cial in patients with CHF in terms of morbidity and mortality (69) , but this drug has been shown to augment neurohormonal activity (70) . Moxonidine has been shown to reduce neurohormonal activation, but in the MOXCON trial it increased mortality (71) .
Phosphodiesterase inhibitors (e.g. amrinone, vesnarinone and pimobendan), which have shortterm haemodynamic bene ts in heart failure, can inhibit the production of TNF and other cytokines from stimulated human lymphocytes (39, 72) . However, it should be noted that phosphodiesterase inhibitors are also related to an adverse prognosis in CHF. Cardiac glycosides can also reduce levels of IL-6 and TNF in vivo (73) . In a double-blind, randomized, placebo-controlled study in CHF patients treated with ACE inhibitors and b-blockers, therapy with pentoxifylline (dose 400 mg three times per day) did not reduce TNF levels (74) .
The value of anticytokine therapy in the management of CHF is highly controversial. Fish oil supplementation decreased plasma concentrations of IL-1b and improved cachexia in dogs with severe congestive heart failure (75) . This may seem a rather basic form of anticytokine drug therapy; it suggests that this kind of therapy may be useful in treating patients with advanced CHF. In CHF patients in NYHA class III and IV, initial studies with a TNF receptor fusion protein (etanercept) have suggested short-and medium-term safety (76, 77) as well as haemodynamic and clinical bene ts (77) . Subsequently, large-scale studies [RENAIS-SANCE, RECOVER (78)] were initiated in CHF patients in NYHA class II -IV using doses of etanercept that were in some treatment groups higher than those used before. These studies were stopped prematurely because it was unlikely that a bene t could be shown with etanercept (79) . Recently, a phase II study in CHF using a TNF antibody (5 or 10 mg kg ¼ 1 remicade for 6 weeks) was also stopped early because initial analyses indicated an increase in mortality in patients on active therapy (80) . The future of anti-TNF therapy in CHF patients is, therefore, very uncertain. Possibly, only patients with proven high TNF levels (such as patients in NYHA class IV or with cardiac cachexia) could bene t from this type of therapy.
Traditional ideas regarding the pathogenesis of chronic heart failure are proving to be inadequate as our understanding of the disease process improves. As a result, this has stimulated the search for other hypotheses to explain the systemic features of this condition. The immune and neurohor-monal abnormalities present in CHF may play a signi cant role, particularly in the development of cardiac cachexia. There is currently no speci c therapy available for patients with cardiac cachexia. It is hoped that further research into this area will lead to the development of new treatments in the future.
